Lung tumors with distinct p53 mutations respond similarly to p53 targeted therapy but exhibit genotype-specific...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Lung adenocarcinoma is a major cause of cancer death, with limited therapeutic options.
• TP53 (p53) mutations occur in about half of lung adenocarcinomas, presenting a therapeutic target.
• The functional impact and therapeutic relevance of different p53 mutations remain unclear.

Purpose of the Study:

• To investigate genotype-independent and genotype-dependent therapeutic sensitivities in p53-mutant lung adenocarcinoma.
• To explore the role of wild-type p53 restoration in suppressing tumor growth.
• To identify specific vulnerabilities associated with different p53 mutation types.

Main Methods:

• Transcriptional and functional analysis of murine KrasG12D-p53null, p53R172H (conformational), and p53R270H (contact) mutant lung tumors.
• In vivo assessment of tumor sensitivity to wild-type p53 restoration.
• Identification of mutation-specific drug sensitivities, including simvastatin.

Main Results:

• Wild-type p53 exerted a dominant tumor-suppressive effect across all p53-deficient genotypes.
• All genotypes showed similar sensitivity to p53 restoration in vivo.
• A p53R270H-specific sensitivity to simvastatin was identified, with a corresponding transcriptional signature found in human lung tumors.

Conclusions:

• p53 targeted therapies show comparable potential across all p53-deficient genotypes.
• The high incidence of p53 loss of heterozygosity in mutant tumors may be linked to wild-type p53's suppressive effect.
• Specific p53 mutations confer distinct vulnerabilities, such as p53R270H-mutant tumors' sensitivity to simvastatin, suggesting clinically relevant therapeutic strategies.